Apellis Pharmaceuticals, Inc. — Director's Dealing 2019

Feb 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2019-02-08

Reporting Person: Watson David O. (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-08	Stock option (right to buy)	$13.85	A	40000	Acquired	2029-02-07	Common Stock (40000)	Direct

Footnotes

F1: This option was granted on February 8, 2019 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.